Neurology

INTRODUCTION

Multiple sclerosis is an autoimmune neurodegenerative disease that mainly affects young people 30 years old and older and has unfortunately shown an upward trend in the last decade, affecting even younger people in their 20s. It mainly affects the central nervous system by causing inflammation and destruction of myelin, the protective layer that surrounds nerve cells. It is a multifactorial disease that leads to the gradual degeneration of the nervous system. Like most autoimmune diseases, multiple sclerosis, unfortunately, shows a degenerative trend and an upward trend in newly diagnosed patients. Existing treatments focus on suppressing the immune system by slightly improving the daily life of specific patients, which for young patients plays a dominant role in their survival.

A similar degeneration to that of multiple sclerosis is caused by vascular dementia, which appears mainly after a stroke, triggering the mechanisms of inflammation, oxidation and finally neurodegeneration, just like multiple sclerosis.

PRODUCT INFORMATION

Neuroaspis is, probably, the first specially designed nutraceuticals in the management of the symptoms of patients with multiple sclerosis (MS) and other similar neurodegenerative diseases such as vascular dementia. Neuroaspis manages the symptoms of MS patients in any stage by achieving the best cellular communication.  Cellular communication is achieved by the correct ration of omega fatty acid ( Ω-3 & Ω-6 fatty acids). In addition, Neuroaspis has a strong anti-inflammatory action activating anti-inflammatory cytokines and suppressing the production of inflammatory ones. A basic component of the cell membrane, and strong anti-inflammatory, are the omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) but also the omega-6 fatty acids linoleic acid (LA) and gamma-linolenic acid (GLA). The product has a strong antioxidant effect against both oxygen and hydrogen free radicals. Basic antioxidant ingredients with specialized action are γ-tocopherol, β-carotene and vitamin E. Neuroaspis has a neuroprotective effect by activating proteins that protect nerve cells from further degeneration.

NEUROASPIS is the only supplement formulation in EU with patent and phase II & III clinical studies, published in BMJ.

http://www.neuroaspis.com/wp-content/uploads/2016/03/BMJ-Open-2013.pdf

https://neurologyopen.bmj.com/content/4/2/e000334

INTRODUCTION

Parkinson's disease is one of the most common neurodegenerative diseases, affecting approximately 1% of the population over 65 years old and mainly men. The main cause is the degeneration of the nerve cells that regulate movement, causing mainly motor symptoms. Current treatment options focus on these symptoms. However, there are some symptoms such as gastrointestinal disturbances, depression and sleep disturbances (known as non-motor symptoms) that appear even before the diagnosis and get worse as the disease progresses. The common feature of all of the above is the impact on patients' quality of life. Current treatment options focus on antidiarrheal and pain relievers, treating symptoms individually.

PRODUCT INFORMATION

Sedoaspis is a product specially designed for the management of non-motor symptoms of Parkinson's disease. Sedoaspis is based on postbiotics that work on the gut-brain axis. Sedoaspis improves intestinal motility and helps reduce gastrointestinal disorders. The main ingredient with a strong effect on the gut is the postbiotic butyric acid, which improves intestinal motility by relieving pain and regulating the levels of neurotransmitters such as serotonin and dopamine. Butyric acid is produced during the fermentation of the food within the probiotics. In addition, Sedoaspis has a strong antioxidant and anti-depressant effect. The main antioxidant ingredient is the stigma of the plant Crocus sativus L, which is a plant with a long history and use. Saffron stigma (the bioactive part of the plant) has a high antioxidant character. Finally, Sedoaspis has an anti-inflammatory effect and meets the needs of patients with Parkinson's disease in vitamin D3.

Coming soon